sEV CD147 Drives HCC Angiogenesis via PI3K/Akt

Hepatocellular carcinoma (HCC) is highly vascularized, and angiogenesis contributes to tumor expansion, invasion, and metastatic dissemination. In the reference study, Huang et al. examined whether small extracellular vesicle (sEV)-associated CD147 could connect these biological processes with a clinically accessible plasma biomarker. Their work is important because it treats CD147-positive sEVs not only as a diagnostic signal, but also as functional mediators of communication between HCC cells and endothelial cells.

The study, published in Extracellular Vesicles and Circulating Nucleic Acids, combined patient plasma analysis, tumor-cell-derived vesicle experiments, endothelial functional assays, and an in vivo angiogenesis model. The resulting evidence places CD147-positive sEVs upstream of VEGFA induction and endothelial activation through the PI3K/Akt pathway. The findings are reported in the reference study by Huang and colleagues.

Study Background and Research Question

Existing HCC screening commonly uses alpha-fetoprotein, imaging, and, when necessary, tissue examination. Each approach has limitations: alpha-fetoprotein does not identify every tumor reliably, imaging is less informative for very small lesions, and biopsy is invasive. These constraints have encouraged interest in circulating extracellular vesicles, which can carry membrane proteins and molecular signals released by tumor cells.

CD147, also known as basigin, is associated with malignant progression and vascular remodeling in several cancer contexts. The central research question was therefore twofold: are CD147-positive sEVs enriched in the circulation of people with HCC, and can HCC-derived CD147-positive sEVs directly promote endothelial behaviors associated with angiogenesis? The investigators also asked whether PI3K/Akt signaling and VEGFA provide a mechanistic explanation for those effects.

Key Innovation from the Reference Study

The main innovation is the integration of biomarker discovery with a functional vesicle mechanism. Rather than measuring CD147 only in tumor tissue, the authors quantified CD147-positive sEVs in plasma and compared HCC samples with liver cirrhosis and healthy donor groups. This design addresses a clinically relevant problem: a biomarker must be detectable in a minimally invasive sample and should ideally reflect a process relevant to disease biology.

The second advance is the use of tumor-cell-derived vesicles to model paracrine signaling. The study did not stop at showing that CD147-positive sEVs are more abundant in HCC-associated plasma. It tested whether vesicles released by HepG2 cells could alter endothelial proliferation, migration, invasion, and tube formation. This combination supports a model in which sEV-associated CD147 participates in the tumor vascular niche rather than serving as a passive disease correlate.

Mechanistically, the authors connect the vesicle signal to increased VEGFA through PI3K/Akt activation. Because VEGFA is a central endothelial growth and permeability factor, this link gives the CD147-positive sEV phenotype a plausible downstream effector. The work consequently frames vesicle-associated CD147 as both a candidate diagnostic marker and a potential entry point for studying HCC angiogenesis.

Methods and Experimental Design Insights

The clinical component used nano-flow cytometry (nFCM) to detect CD147 expression on plasma-derived sEVs. According to the published study, the analysis included 155 patients with HCC, 59 patients with liver cirrhosis, and 82 healthy donors. The inclusion of cirrhosis is particularly valuable because chronic liver disease is a clinically relevant comparison group and can complicate interpretation of tumor-associated circulating signals.

The authors also examined CD147 expression in HCC tissue relative to normal tissue. For functional experiments, CD147-positive sEVs derived from HepG2 cells were applied to human umbilical vein endothelial cells (HUVECs). Endothelial proliferation was assessed with a cell proliferation assay, directional movement with a scratch wound-healing assay, and motility or invasiveness with a transwell assay. Tube formation provided a widely used in vitro surrogate for endothelial network assembly.

To extend the observations beyond cultured cells, the investigators used an in vivo Matrigel plug angiogenesis assay. This model can show whether a treatment or biological material supports vascular infiltration in a three-dimensional extracellular matrix environment. The study then evaluated PI3K/Akt pathway activity and VEGFA expression to relate the endothelial phenotype to a molecular mechanism.

Protocol Parameters

• Clinical comparison: The literature-backed cohort comprised 155 HCC patients, 59 liver cirrhosis patients, and 82 healthy donors, with plasma CD147-positive sEVs measured by nFCM; these values are reported in the reference article.
• Vesicle source: Use HepG2-derived CD147-positive sEVs for the tumor-to-endothelium model described by the study, and include non-HCC or CD147-reduced vesicle controls in follow-up experiments to separate vesicle effects from CD147-specific effects.
• Endothelial readouts: Pair proliferation, scratch closure, transwell migration or invasion, and tube formation rather than relying on a single assay. The first four readouts were part of the reported experimental framework; control selection and normalization should be optimized for the chosen laboratory system.
• Mechanistic validation: Measure pathway phosphorylation and VEGFA together with endothelial phenotypes. A pharmacological Akt perturbation or an orthogonal genetic approach can be used as a follow-up test of pathway dependence, but such optimization is a suggested extension rather than a parameter established by the cohort analysis.
• In vivo confirmation: The reported Matrigel plug model provides an additional angiogenesis endpoint. For reproducibility, investigators should predefine vesicle dose normalization, plug analysis criteria, and biological replicate requirements rather than infer them from the clinical sample size.

Core Findings and Why They Matter

CD147 expression was higher in HCC tissue than in normal tissue, and the number of CD147-positive sEVs in plasma was significantly higher in HCC than in both cirrhosis and healthy donor groups. This result supports the clinical relevance of vesicle-associated CD147, while the cirrhosis comparison suggests that the signal may carry information beyond generalized chronic liver injury. Nevertheless, the finding establishes a candidate marker, not a validated standalone diagnostic test.

In the functional arm, HepG2-derived CD147-positive sEVs increased HUVEC proliferation, migration, invasion, and tube formation. The convergence of these endpoints is meaningful: proliferation reflects endothelial expansion, migration and invasion reflect movement through matrix or across a barrier, and tube formation captures network organization. Together, they indicate a broad proangiogenic response rather than an isolated change in one cell behavior.

The molecular results showed that the vesicles increased VEGFA through activation of PI3K/Akt signaling. This provides a mechanistic bridge from a tumor-derived extracellular signal to an endothelial phenotype. It also suggests that measuring only vesicle abundance may miss important biological variation: two patients could have similar numbers of circulating sEVs but different CD147 content or different capacity to activate endothelial signaling.

For HCC research, the study has two practical implications. First, CD147-positive sEV quantification could be developed alongside established clinical variables, especially in patients for whom conventional markers are inconclusive. Second, the vesicle–endothelium assay system offers a way to test whether disrupting Akt signaling, CD147 activity, or VEGFA output reverses the angiogenic phenotype. Those experiments could help distinguish association from causality and clarify whether vesicle-associated CD147 is a useful intervention point.

Comparison with Existing Internal Articles

The internal article O-GlcNAcylation Drives Wnt-Induced Glycolysis in Bone Formation addresses a different tissue and disease context, but it provides a useful conceptual comparison. Both studies connect a signaling input to a measurable cellular phenotype: the HCC paper links sEV-associated CD147 to PI3K/Akt-dependent angiogenesis, whereas the bone study links O-GlcNAcylation and Wnt signaling to glycolytic remodeling in osteoblasts. The comparison underscores that pathway interpretation should remain tied to cell type, stimulus, and functional endpoint rather than treating a signaling pathway as disease-specific.

Methodologically, the HCC study is distinguished by its translational sequence: patient plasma profiling leads to vesicle transfer experiments and then to an in vivo angiogenesis assay. That progression is complementary to intracellular metabolism-focused studies and illustrates why biomarker research benefits from pairing clinical measurement with mechanistic validation.

Limitations and Transferability

The study provides strong evidence for an association between circulating CD147-positive sEVs and HCC, but clinical translation requires independent validation. Diagnostic performance should be tested in separate cohorts, with attention to tumor stage, underlying liver disease, treatment status, and preanalytical factors affecting vesicle recovery. The reported comparison with cirrhosis is encouraging, yet it does not by itself establish sensitivity, specificity, or superiority over alpha-fetoprotein and imaging.

Biological transferability is also limited by the experimental models. HepG2 cells represent one HCC background, while HUVECs are a convenient endothelial model rather than a complete representation of liver sinusoidal endothelial cells or tumor-associated vascular cells. Plasma sEVs are heterogeneous and may originate from several tissues, so circulating CD147-positive vesicles cannot automatically be assigned to malignant cells without additional source-tracing evidence.

The pathway interpretation is plausible and experimentally supported by the reported increase in PI3K/Akt activity and VEGFA. However, future work should apply orthogonal perturbations and rescue designs to determine whether CD147 is required for vesicle uptake, pathway activation, VEGFA induction, or several steps in the sequence. Testing additional HCC models and primary endothelial systems would further establish whether the mechanism is broadly transferable.

Overall, the most defensible outlook is that CD147-positive sEVs warrant development as a mechanistically informed HCC biomarker and as a tool for investigating tumor-driven vascular remodeling. The next steps should preserve the study’s integrated logic: validate the circulating signal clinically, reproduce the endothelial phenotype in more physiologically relevant systems, and determine whether pathway inhibition reverses the effects attributed to the vesicles.

Research Support Resources

For follow-up pathway perturbation experiments, researchers can use MK-2206 dihydrochloride (SKU A3010) to support similar workflows testing whether Akt suppression changes sEV-induced endothelial responses. MK-2206 is a selective allosteric Akt1/2/3 inhibitor and can be incorporated into a PI3K/Akt/mTOR signaling pathway inhibitor design with vehicle, untreated-vesicle, and CD147-modified-vesicle controls. Depending on the model, downstream measurements may include VEGFA, migration, tube formation, or an apoptosis assay when cancer cell apoptosis is part of the research question. The compound is intended for scientific research only; handling and storage should follow the product information.